alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Science Foundation

The National Science Board hereby gives notice of the scheduling of a teleconference of the Committee on Strategy for the transaction of National Science Board business pursuant to the NSF Act and the Government in the Sunshine Act.

# TIME AND DATE:

Friday, April 29, 2022, from 10:00-10:30 a.m. EDT.

# PLACE:

This meeting will be held by teleconference organized through the National Science Foundation.

# STATUS:

Closed.

# MATTERS TO BE CONSIDERED:

The agenda is: Committee Chair's Opening Remarks; Approval of Prior Meeting Minutes; Update on NSF's FY 2022 Current Plan.

# CONTACT PERSON FOR MORE INFORMATION:

                        Point of contact for this meeting is: Chris Blair,                         *cblair@nsf.gov,*                         703/292-7000. Meeting information and updates are available from the NSB website at                         *https://www.nsf.gov/​nsb/​meetings/​index.jsp#up.*

Chris Blair,

Executive Assistant to the National Science Board Office.

[FR Doc. 2022-09041 Filed 4-25-22; 8:45 am]

BILLING CODE 7555-01-P
Ray Wilbur PAYN, petitioner, v. Gerald E. KELLEY, et al.

No. 17-824.

Supreme Court of the United States

Feb. 20, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.
NEXT MILLENIUM REALTY, LLC, et al., petitioners, v. ADCHEM CORPORATION, et al.

No. 17-468.

Supreme Court of the United States

Dec. 4, 2017.

Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.
OPENET TELECOM, INC., et al., petitioners, v. AMDOCS (ISRAEL) LIMITED.

No. 17-136.

Supreme Court of the United States

Nov. 27, 2017.

*470Petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit denied.
James DAWSON, et ux., petitioners, v. Dale W. STEAGER, West Virginia State Tax Commissioner.

No. 17-419.

Supreme Court of the United States

Jan. 8, 2018.

The Solicitor General is invited to file a brief in this case expressing the views of the United States.
<PAGE>

                                                                   Exhibit 10.36

                            ROSETTA BIOSYSTEMS, INC.

                                 April 17, 1997

Mr. John King


Dear John:

         This letter is to confirm the offer by Rosetta Biosystems, Inc. (the
"Company") to employ you in the position of Senior Vice President, Chief
Operating Officer and Chief Financial Officer as of April 15, 1997 (the "Start
Date"). As we have discussed, you will be paid a starting salary of $10,000 per
month.

         In connection with the commencement of your employment, the Company has
agreed to sell you 164,415 shares of the Company's Common Stock (the "Shares")
with a purchase price of $0.01 per share. The shares are subject to the
Company's right of repurchase and such repurchase right will lapse with respect
to one-twelfth of the total number of Shares each month beginning on May 15,
1997. The purchase of the Shares are subject to the terms and conditions of a
Common Stock Purchase Agreement to be entered into between you and the Company.

         Your employment with the Company will be on an "at will" basis, meaning
that either you or the Company may terminate your employment at any time for any
reason or no reason, without further obligation or liability. Notwithstanding
the foregoing, if you are terminated, other than for cause, the Company's right
of repurchase will lapse with respect to all Shares as of the date of such
termination.

         In connection with the commencement of your employment, the Company
will recommend that the Board of Directors grant you an option to purchase
493,245 shares (SUBJECT TO STOCK SPLITS OR RECAPITALIZATIONS)of the Company's
Common Stock (the "OPTION SHARES") with an exercise price equal to the fair
market value on the date of the grant. These Option Shares would begin vesting
on May 15, 1998 and vest at the rate of 1/36th of the total number of Option
Shares each month. Vesting will, of course, depend on your continued employment
with the Company and termination of your employment for any reason would
terminate vesting immediately. The option will be an incentive stock option to
the maximum extent allowed by the tax code and will be subject to the terms of
the Company's 1997 Stock Option Plan and the Stock Option Agreement between you
and the Company.

         Your acceptance of this offer and commencement of employment with the
Company is contingent upon the execution, and delivery to an officer of the
Company, of the Company's


<PAGE>

Confidential Information and Invention Assignment Agreement, a copy of which is
enclosed for your review and execution (the "CONFIDENTIALITY AGREEMENT").

         John, we are all looking forward to working with you and hope you will
accept this offer and join us in our effort to create the Company's future.

                                                  Sincerely yours,

                                                  Stephen H. Friend
                                                  President

Accepted and Agreed:

_________________________
John King

Date:____________
```
  
 
VIX FUTURES - CBOE FUTURES EXCHANGE                                  Code-1170E1
OPTION AND FUTURES COMBINED POSITIONS AS OF 12/14/10          |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  Long  | Short  |Spreads |  Long  | Short  |  Long  | Short  |  Long  | Short
--------------------------------------------------------------------------------
($1000 X INDEX)                                      OPEN INTEREST:      151,504
COMMITMENTS
  12,552   22,466   31,732   91,648   85,276  135,932  139,474   15,572   12,030

CHANGES FROM 12/07/10 (CHANGE IN OPEN INTEREST:      2,273)
   2,595      635   -1,466      307    5,727    1,436    4,896      837   -2,624

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADER
     8.3     14.8     20.9     60.5     56.3     89.7     92.1     10.3      7.9

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:       91)
      22       27       36       25       32       70       80
```

----

Updated December 17, 2010
# Official Journal C 453/30 D

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 453 |
| | |
| English edition | Information and Notices | Volume 6330 December 2020 |

ISSN 1977-091X

Official Journal

of the European Union

C 453

English edition

Information and Notices

Volume 6330 December 2020

---

| Contents | page |
| --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2020/C 453/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2020 to 30 November 2020(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |
| 2020/C 453/02 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2020 to 30 November 2020(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 13 |

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2020/C 453/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2020 to 30 November 2020(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

1

2020/C 453/02

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2020 to 30 November 2020(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

13

---

| EN | |
| --- | --- |

EN
<PAGE>
                                                                   Exhibit 10.18


                             Consulting Agreement

   This agreement made effective the 1st day of  April, 1999


   BETWEEN:
                         ThinWeb Software Incorporated
                         Suite 101, Phase 3
                         6 Antares Drive
                         Ottawa, Ontario K2E 8A9

                         hereinafter referred to as the ("Client")


    AND:

                         J. S. Anthony & Co. Ltd.
                         158 Amelia Street
                         Toronto, Ontario M4X 1E7

                         hereinafter referred to as the ("Consultant")



   1.0 Services

   The Consultant shall provide guidance to Client (and any affiliates) on
   financing, business strategy and corporate development matters including to
   assist and represent the Client in financial negotiations, assist in locating
   suitable board structure and membership, assist in locating and negotiating
   with senior executive candidates,  and such other similar activities as the
   Client may direct.

   Services of the Consultant shall be provided by James Anthony.


   2.0 Payment

   Consultant will be paid a monthly retainer of $5,000 (five thousand dollars)
   for performance of the services.

   All Consultant expenses pre-approved by the Client will be reimbursed through
   the Client's internal expense reimbursement process.

   3.0 Term

   This Agreement shall run month to month until terminated by either party upon
   30 day's notice.


   4.0 Proprietary Information

   The Consultant will maintain all information obtained directly or indirectly
   as a consequence of performing the Services in confidence, whether such
   information is supplied by Client or has been created by the Consultant in
   the course of its activities relating to the Services.
<PAGE>

   The Consultant will not, without Client' prior written consent, disclose such
   information to others nor make any use of such information except hereunder.


   In signing this Agreement, the parties have caused this Agreement to be
   executed by their authorized representatives on the dates noted below:



   Client                                   Consultant



By:                                      By:
   ------------------------------------     ------------------------------------
     Authorized Signature                     Authorized Signature

     James Cappadocia                         James Anthony
   ------------------------------------     ------------------------------------
     Typed or Printed Name                    Typed or Printed Name

     President and Chief Executive            Principal
     Officer
   ------------------------------------     ------------------------------------
     Title                                    Title

     March    , 2000                          March   , 2000
   ------------------------------------     ------------------------------------
     Date                                     Date
EXHIBIT 32.1 – CEO
Certification








ROYAL INVEST INTERNATIONAL
CORP.





CERTIFICATION PURSUANT
TO


18 U.S.C. SECTION
1350,


AS ADOPTED PURSUNT
TO


SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002








In
connection with the Annual Report of Royal Invest International Corp.
(the "Company") on Form 10-K for the year ended December 31, 2007 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Jerry Gruenbaum, CEO of the Company, certify, pursuant to 18 U.S.C.ss. 1350, as
added by ss. 906 of the Sarbanes-Oxley Act of 2002, that:





1.         The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





2.         The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company as of and for
the period covered by the Report.








By: /s/ Jerry
Gruenbaum


Jerry
Gruenbaum, CEO





August
26, 2008





A signed
original of this written statement required by Section 906 of the Sarbanes-Oxley
Act of 2002 ("Section 906"), or other document authenticating, acknowledging, or
otherwise adopting the signature that appears in typed form within the
electronic version of this written statement required by Section 906, has been
provided to Royal Invest International Corp., and will be retained by Royal
Invest International Corp. and furnished to the Securities and Exchange
Commission or its staff upon request.
Exhibit 32



CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION
1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



I, Jimmy S.M. Lee,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Integrated Silicon Solution, Inc. on Form 10-Q for the quarterly period ended December 31, 2003 fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of
Integrated Silicon Solution, Inc.



By:

/s/    JIMMY S.M.
LEEJimmy S.M. Lee Chairman of the Board and Chief Executive OfficerJanuary 26, 2004




I, Gary L. Fischer, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Integrated Silicon Solution, Inc. on Form 10-Q for the quarterly period ended December 31, 2003 fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of
Integrated Silicon Solution, Inc.



By:

/s/    GARY L.
FISCHERGary L. Fischer President, Chief Operating Officer and Chief Financial OfficerJanuary 26, 2004
Exhibit 31.3

                                  CERTIFICATION

I, PATRICIA GRAHAM, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Global Aircraft
Solutions, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.


Date: May 14, 2005



                                            /s/  Patricia Graham
                                            ------------------------------------
                                                 Patricia Graham,
                                                 Principal Financial Officer
Frederick BANKS, petitioner, v. Allissa MARQUEZ, et al.

No. 17-5668.

Supreme Court of the United States

Oct. 2, 2017.

Motion of petitioner for leave to proceed *in forma pauperis* denied, and petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit dismissed. See Rule 39.8.
Darrel A. WHITE, petitioner, v. Dwayne A. TURNER, et al.

No. 16-8906.

Supreme Court of the United States

Oct. 2, 2017.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
**EXHIBIT      32.1**

**and**

**EXHIBIT      32.2**

| (1)   | The                Report fully complies with the requirements of Section 13(a) or 15(d)                of                the Securities Exchange Act of 1934;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                             |   |   |   |
|----------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
| /s/              John              Probandt                                                                                 |   |   |        |
|                                                                                                                                  |   |   |        |
| Name:                John ProbandtTitle:                Chief Executive and Financial OfficerDate:                April 27, 2007 |   |   |        |

----
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM VOICE &
WIRELESS CORP AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         764,715
<SECURITIES>                                         0
<RECEIVABLES>                                  438,076
<ALLOWANCES>                                         0
<INVENTORY>                                    277,831
<CURRENT-ASSETS>                             1,509,297
<PP&E>                                         746,475
<DEPRECIATION>                                 439,134
<TOTAL-ASSETS>                               2,942,884
<CURRENT-LIABILITIES>                          322,944
<BONDS>                                        322,998
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     7,235,011
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 2,942,884
<SALES>                                        644,849
<TOTAL-REVENUES>                               644,849
<CGS>                                          453,977
<TOTAL-COSTS>                                  453,977
<OTHER-EXPENSES>                               431,564
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              23,317
<INCOME-PRETAX>                              (236,079)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (236,079)
<EPS-BASIC>                                      (.03)
<EPS-DILUTED>                                    (.03)


</TABLE>